(SESN) – Press Releases
-
Carisma Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
-
Sesen Bio Stockholders Approve Merger with Carisma Therapeutics
-
Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results
-
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote “FOR” All Proposals to Approve Pending Merger With Carisma
-
Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meeting
-
Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Merger
-
BML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics
-
Sesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending Merger
-
Sesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics Merger
-
Sesen Bio Receives NASDAQ Delisting Notice
-
Sesen Bio Reiterates Confidence that Pending Merger with Carisma is in Best Interests of Stockholders
-
Investor Group Issues Letter to the Boards of Sesen Bio and Carisma Rejecting Their Apparent Attempt to Purchase Merger Support
-
Sesen Bio Files Definitive Proxy Statement and Mails Letter to Stockholders in Connection with Pending Merger with Carisma Therapeutics
-
Investor Group Issues Letter to Sesen Bio’s Board of Directors Regarding Intent to Vote AGAINST Proposed Carisma Merger
-
Sesen Bio Reiterates Confidence in Pending Merger with Carisma Therapeutics
-
Investor Group Reiterates Intent to Vote AGAINST Sesen Bio’s Value-Destructive Merger with Carisma
-
Sesen Bio and Carisma Therapeutics Announce Substantial Increase to Expected Special Cash Dividend in Connection with Pending Merger
-
Sesen Bio Reports Third Quarter 2022 Financial Results and Business Update
-
Sesen Bio and Carisma Therapeutics Announce Merger Agreement
-
Sesen Bio Reports Second Quarter 2022 Financial Results and Business Update
-
Sesen Bio Announces Strategic Decision to Pause Clinical Development of Vicineum™ in the US
-
Sesen Bio Reports First Quarter 2022 Financial Results and Business Update
-
Sesen Bio Provides Strategic Update
-
Sesen Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Anticipated Regulatory Path Forward for the Company’s Lead Product Candidate, Vicineum™
-
Sesen Bio Further Enhances Team with Key Hires
-
Sesen Bio Announces Anticipated Regulatory Path Forward for Vicineum™
-
Sesen Bio Strengthens Medical Team
-
Sesen Bio Director Jane Pritchett Henderson Transitions to CEO Advisor Role
-
22nd Century Group Announces CFO Transition
-
Sesen Bio Reports Third Quarter 2021 Financial Results and Business Update
-
Sesen Bio Announces Productive CMC Type A Meeting with the FDA
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against View, Sesen Bio, Generac, and Paypal and Encourages Investors to Contact the Firm
-
Sesen Bio Expands CMC and Clinical Teams
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Yalla, Sesen Bio, HyreCar, and loanDepot and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Yalla, Sesen Bio, HyreCar, and loanDepot and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Yalla, Sesen Bio, and loanDepot and Encourages Investors to Contact the Firm
-
INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of ANVS, PYPL, SAVA, SESN Investors, Lead Plaintiff Deadlines Set
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Yalla, Sesen Bio, and loanDepot and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CorMedix, Koninklijke Philips, and Sesen Bio and Encourages Investors to Contact the Firm
-
ANVS, ATVI, SESN, ZY SHAREHOLDERS - ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action lawsuits filed on behalf of Investors, Lead Plaintiff Deadlines Set
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CorMedix, Koninklijke Philips, and Sesen Bio and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Orphazyme, CorMedix, Koninklijke Philips, and Sesen Bio and Encourages Investors to Contact the Firm
-
INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of ANVS, ATVI, SESN, ZY Investors, Lead Plaintiff Deadlines Set
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Orphazyme, CorMedix, Koninklijke Philips, and Sesen Bio and Encourages Investors to Contact the Firm
-
Sesen Bio Receives Complete Response Letter from FDA for Vicineum™ (oportuzumab monatox-qqrs)
-
Sesen Bio Strengthens Executive Leadership Team as the Company Approaches the Potential Approval and Commercial Launch of Vicineum™
-
Sesen Bio Reports Second Quarter 2021 Financial Results and Significant Global Progress for Vicineum™
-
Sesen Bio Announces Partnership with Eczacibasi Pharmaceuticals Marketing (EIP) for the Commercialization of Vicineum™ in Turkey
-
Sesen Bio Strengthens Leadership Team as the Company Approaches the Potential Approval and Launch of Vicineum™
-
Sesen Bio Announces Significant Commercial Progress as the Company Approaches the Potential Approval and Launch of Vicineum™ in the US
Back to SESN Stock Lookup